OncoMatch

OncoMatch/Clinical Trials/NCT07830134

Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback

Is NCT07830134 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for medulloblastoma, childhood.

NARecruitingSt. Jude Children's Research HospitalNCT07830134Data as of Oct 2026

This study will evaluate a new way to help childhood medulloblastoma survivors improve their thinking and memory skills. Many survivors experience long term challenges with attention and working memory because of the tumor and its treatments. The study uses real time neuroimaging technologies such as real time functional magnetic resonance imaging (rt-fMRI) and real time functional near infrared spectroscopy (rt-fNIRS) make it possible to monitor and display a participant's brain activity as it occurs. Neurofeedback uses this activity to provide individuals with immediate visual information about how specific brain regions are functioning, potentially enabling them to learn strategies to modulate or improve brain activity linked to thinking skills. Participants are randomly assigned to one of two groups. One group receives feedback from a brain area involved in working memory, and the other receives feedback from a different brain region as a comparison. Over three visits, participants complete brain scans, neurofeedback sessions, and thinking and memory tests. The main goal is to see if this type of brain training is practical, safe, and comfortable for survivors. The study also looks at whether the training may help improve brain activity and working memory performance. Primary Objective(s): • To evaluate the feasibility of real time Hemo-NFB neurofeedback training in medulloblastoma survivors. Secondary Objective(s): • To estimate the initial efficacy of Hemo-NFB neurofeedback to up-regulate the activity of the dorsolateral prefrontal cortex (DLPFC) and improve WM performance.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Demographics

Ages 10–25

Prior therapy

Must have received: craniospinal radiotherapy — upfront for medulloblastoma

received treatment for medulloblastoma with upfront craniospinal radiotherapy (proton or photon)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • St. Jude Children's Research Hospital · Memphis, Tennessee

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07830134 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received craniospinal radiotherapy.

Is there an age limit?

Yes. Patients must be 25 years or younger and at least 10 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Related pages

Glioblastoma trials